Results 51 to 60 of about 63,889 (276)

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial

Scientific Reports, 2018
We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG.
Masaaki Mori, Takuma Hara, Masako Kikuchi, Hiroyuki Shimizu, Tomoyuki Miyamoto, Satoru Iwashima, Tatsuya Oonishi, Kunio Hashimoto, Norimoto Kobayashi, Kenji Waki, Yasuo Suzuki, Yoshikazu Otsubo, Hiroshi Yamada, Chikao Ishikawa, Taichi Kato, Shigeto Fuse   +15 more
doaj   +1 more source

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy

Case Reports in Gastroenterology, 2009
Tumor necrosis factor α plays an important role in the pathogenesis of Crohn’s disease (CD). The effects of infliximab on gastrointestinal bleeding in CD have not yet been fully evaluated.
Manzurul Chowdhury, Norihiko Kudara, Toshimi Chiba, Masaki Endo, Risaburo Akasaka, Kazumitsu Tomita, Saori Fujiwara, Tomomi Mizutani, Tamotsu Sugai, Yasuhiro Takikawa, Kazuyuki Suzuki   +10 more
doaj   +1 more source

Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome

, 2015
Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases.
Serpil Tuna, Sevil Alan, Elif Betül Türkoğlu   +2 more
core   +1 more source

Penfluridol Triggers GSDME‐Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy

Advanced Science, EarlyView.
A high‐throughput screen of FDA‐approved antipsychotics identifies penfluridol as a potent pyroptosis inducer acting via direct TTI1 inhibition. This triggers TNFA‐NFKB signaling and caspase‐8/‐3‐dependent GSDME cleavage. The compound stimulates antitumor immunity alone and synergizes with anti‐PD‐1 therapy, while low TTI1 expression emerges as a ...
Linfeng Li, Daishi Li, Danyao Chen, Yating Dian, Lei Yao, Hui Su, Ziyu Guo, Deze Zhao, Zihua Wu, Furong Zeng, Chunfang Zhang, Guangtong Deng   +11 more
wiley   +1 more source

Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

BMJ Open
Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and ...
Jonathan P Segal, Mayur Garg, Miles P Sparrow, Gareth J Walker, Ashish Srinivasan, Peter De Cruz, Desmond Chee, Alex Boussioutas, Robert V Bryant, Georgina Hold, Gregory T Moore, Susan J Connor, Robert D Little, Mark G Ward, Jo McKenzie, Patrick Hilley, Robert B Gilmore, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, Kate Lynch, Jane Andrews, Yoon K An, Emily K Wright   +24 more
doaj   +1 more source

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Pharmaceutics, 2021
Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates.
Christina Schräpel, Lukas Kovar, Dominik Selzer, Ute Hofmann, Florian Tran, Walter Reinisch, Matthias Schwab, Thorsten Lehr   +7 more
doaj   +1 more source

Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease

Advanced Science, EarlyView.
An orally administered prebiotic polysaccharide hydrogel (predaGel) based on inulin and alginate‐dopamine is stable in the stomach, adheres to the intestine, and degrades slowly in the colon. It enables site‐specific delivery of anti‐TNF‐α and anti‐IL‐12/23 antibodies, scavenges reactive oxygen species, and remodels gut microbiota, offering effective ...
Xinyi Dong, Huan He, Li Cao, Fenghua Meng, Zhiyuan Zhong   +4 more
wiley   +1 more source

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. [PDF]

, 2011
International audienceINTRODUCTION: A proportion of patients receiving infliximab have antibodies toward infliximab (ATI), which are associated with increased risk of infusion reaction and reduced response to treatment.
Ducourau, Emilie, Emilie Ducourau, Hervé Watier, Francine Lauféron, David Ternant, Denis Mulleman, Delphine Miow Lin, Ternant, David, Lauféron, Francine, Philippe Goupille, Mulleman, Denis, Watier, Hervé, Paintaud, Gilles, Miow Lin, Delphine Chu, Goupille, Philippe, Gilles Paintaud   +15 more
core   +1 more source

Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid‐2026

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Inflammatory bowel disease management has undergone a major transformation with the introduction of treat‐to‐target strategies and highly effective biologic and small‐molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative ...
Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama   +4 more
wiley   +1 more source

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. [PDF]

PLoS ONE, 2017
Infliximab is an effective treatment for inflammatory bowel disease (IBD). Studies differ regarding the influence of body mass index (BMI) on the response to infliximab, with the majority of studies indicating that increased BMI may be associated with a ...
Franco Scaldaferri, Daria D'Ambrosio, Grainne Holleran, Andrea Poscia, Valentina Petito, Loris Lopetuso, Cristina Graziani, Lucrezia Laterza, Maria Teresa Pistone, Silvia Pecere, Diego Currò, Eleonora Gaetani, Alessandro Armuzzi, Alfredo Papa, Giovanni Cammarota, Antonio Gasbarrini   +15 more
doaj   +1 more source